## **Supplementary Online Content**

Jang SR, Nikita N, Banks J, et al. Association between sex and immune checkpoint inhibitor outcomes for patients with melanoma. *JAMA Netw Open.* 2021;4(12):e2136823. doi:10.1001/jamanetworkopen.2021.36823

**eTable.** Distribution of Death Between Female and Male Advanced Melanoma Patients, by Subgroup

**eFigure 1.** Overall Survival for the Entire Patient Cohort, by Sex

**eFigure 2.** Overall Survival for Anti–PD-1 Therapy Patients Without Prior Use of Ipilimumab, by Sex


**eFigure 3.** Overall Survival for Anti–PD-1 Therapy Patients With Prior Use of Ipilimumab, by Sex

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Distribution of Death Between Female and Male Advanced Melanoma Patients, by Subgroup


		Death	
Subgroup	Sex	Yes, n (%)	No, n (%)
Anti-PD1 with Ipilimumab History	Female	45 (39.8%)	68 (60.2%)
	Male	102 (41.0%)	147 (59.0%)
Anti-PD1 without Ipilimumab History	Female	95 (40.6%)	139 (59.4%)
	Male	274 (45.1%)	334 (54.9%)
Combination Therapy with Ipilimumab History	Female	26 (65.0%)	14 (35.0%)
	Male	50 (40.0%)	75 (60.0%)

eFigure 1. Overall Survival for the Entire Patient Cohort, by Sex




The unit of measure for the x-axis (ie, time) is months, and the unit of measure for the y-axis (ie, survival probability) is percent.

eFigure 2. Overall Survival for Anti-PD-1 Therapy Patients Without Prior Use of Ipilimumab, by Sex



The unit of measure for the x-axis (ie, time) is months, and the unit of measure for the y-axis (ie, survival probability) is percent.

eFigure 3. Overall Survival for Anti-PD-1 Therapy Patients With Prior Use of Ipilimumab, by Sex



The unit of measure for the x-axis (ie, time) is months, and the unit of measure for the y-axis (ie, survival probability) is percent.